Walther M M, Johnson B, Culley D, Shah R, Weber J, Venzon D, Yang J C, Linehan W M, Rosenberg S A
Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA.
J Urol. 1998 Mar;159(3):718-22.
We sought to determine the frequency of interleukin-6 (IL-6) expression in renal cancer cell lines, the frequency of the detection of IL-6 in the serum of patients with metastatic renal cell carcinoma, whether serum IL-6 level correlates with the development of paraneoplastic syndromes and whether serum IL-6 level in patients with metastatic renal cancer correlates with response to treatment with interleukin-2 (IL-2) or patient survival.
Conditioned media from 21 cell lines from 20 patients were examined for IL-6. We identified 2 matched groups of patients with metastatic renal cancer (30 responders and 29 nonresponders) to IL-2 based immunotherapy. Stored pretreatment serum specimens were evaluated for IL-6. Medical records were reviewed to determine the presence of paraneoplastic syndromes.
IL-6 was detected in 19 of 21 renal cancer cell lines (90%) obtained from 20 patients with metastatic renal cancer as well as in the serum of 33 of 59 patients (56%) with metastatic renal cell carcinoma. A significant association between serum IL-6 level and anemia (p = 0.0032), elevated platelet count (p = 0.01), decreased albumin (p = 0.034) and elevated alkaline phosphatase (p = 0.04) was found. A trend was noted of the association of increased serum IL-6 level and fever (p = 0.051). No correlation was found between pretreatment serum IL-6 level and survival or response to IL-2.
IL-6 was frequently secreted by renal cancer cell lines but it was only present in the serum of approximately half of the patients with metastatic renal cancer. Elevations of serum IL-6 were associated with paraneoplastic manifestations frequently seen in patients with renal cancer, including anemia, thrombocytosis, decreased albumin and elevations of alkaline phosphatase (Stauffer's syndrome). A weak relationship was noted between serum IL-6 level and fever but none was noted between that and survival or response to IL-2.
我们试图确定白细胞介素-6（IL-6）在肾癌细胞系中的表达频率、转移性肾细胞癌患者血清中IL-6的检测频率、血清IL-6水平是否与副肿瘤综合征的发生相关，以及转移性肾癌患者的血清IL-6水平是否与白细胞介素-2（IL-2）治疗反应或患者生存率相关。
检测了来自20例患者的21个细胞系的条件培养基中的IL-6。我们确定了2组匹配的转移性肾癌患者（30例反应者和29例无反应者）接受基于IL-2的免疫治疗。对储存的治疗前血清标本进行IL-6评估。查阅病历以确定副肿瘤综合征的存在情况。
在从20例转移性肾癌患者获得的21个肾癌细胞系中的19个（90%）以及59例转移性肾细胞癌患者中的33例（56%）血清中检测到IL-6。发现血清IL-6水平与贫血（p = 0.0032）、血小板计数升高（p = 0.01）、白蛋白降低（p = 0.034）和碱性磷酸酶升高（p = 0.04）之间存在显著关联。注意到血清IL-6水平升高与发热之间存在关联趋势（p = 0.051）。治疗前血清IL-6水平与生存率或对IL-2的反应之间未发现相关性。
IL-6在肾癌细胞系中频繁分泌，但仅在大约一半的转移性肾癌患者血清中存在。血清IL-6升高与肾癌患者常见的副肿瘤表现相关，包括贫血、血小板增多、白蛋白降低和碱性磷酸酶升高（斯陶弗综合征）。血清IL-6水平与发热之间存在微弱关系，但与生存率或对IL-2的反应之间未发现关系。
